Barclays analyst Luke Sergott maintained a Hold rating on Certara (CERT – Research Report) today and set a price target of $18.00. The company’s shares closed yesterday at $18.51.
Sergott covers the Healthcare sector, focusing on stocks such as Catalent, Illumina, and Sotera Health. According to TipRanks, Sergott has an average return of -3.5% and a 41.50% success rate on recommended stocks.
Currently, the analyst consensus on Certara is a Hold with an average price target of $18.13.
CERT market cap is currently $3.03B and has a P/E ratio of -53.22.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Certara (CERT) Company Description:
Certara Inc accelerate medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides proven modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trial, accelerate regulatory approval and increase patient access to medicines.
Read More on CERT:
- Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference
- Certara initiated with a Market Perform at JMP Securities
- Certara price target raised to $20 from $17 at UBS
- Certara sees FY24 EPS 41c-46c, consensus 48c
- Certara reports Q4 EPS 9c, consensus 11c
